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Infection with influenza A virus, one of the most common life-threatening viruses, causes the accumulation of
inflammatory cells in the lung, which is directly correlated with influenza-associated morbidity and mortality. In
this study, we investigated the potential of lysozyme-treated Enterococcus faecalis FK-23 (LFK) to prevent influenza
in influenza virus-infected mice. C57BL/6N mice were orally administered LFK and intranasally infected with
influenza virus A/Puerto Rico/8/34 (H1N1) at lethal doses. After infection with influenza A virus, the survival rate of
the LFK-administered mice was significantly higher than that of saline-administered mice. Staining of lung
sections with hematoxylin-eosin, and cell counts of lung and bronchoalveolar lavage fluid showed that oral
administration of LFK suppressed the excessive infiltration of leukocytes into the lung after viral infection.
Extravasation assay revealed that the arrest was mediated by modulation of pulmonary alveolar-capillary
permeability. Expression levels of genes involved in matrix degradation, which are correlated with vascular
permeability, were downregulated in LFK-administered mice. These findings suggest that stabilizing the integrity
of the alveolar-capillary barrier by the administration of LFK improves survival rate.
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Leukocyte influxBackground
Influenza is a highly contagious acute respiratory dis-
ease caused by influenza viruses, which belong to the
Orthomyxoviridae family. According to reports issued
by the World Health Organization, approximately 5–
15% of the world’s population is annually infected
with influenza A virus, and 250, 000–500, 000 of these
infected patients die each year. Annual immunization is
the primary means to protect from influenza virus infec-
tion, but this vaccination strategy can be limited by the
production time (Boltz et al. 2010). In addition to the vac-
cination strategy, antiviral therapy is useful to control the
spread of influenza. Two classes of antiviral drugs (M2-ion* Correspondence: lab@nichinichi-phar.co.jp
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in any medium, provided the original work is pchannel inhibitors and neuraminidase inhibitors) have been
approved for the prevention and treatment of influenza
(Boltz et al. 2010; van der Vries et al. 2011). However, the
effectiveness of these antiviral agents may be limited by the
rapid emergence of drug-resistant viruses (van der Vries
et al. 2011).
Severe influenza virus infection can lead to diffuse alveo-
lar damage, which is characterized by pulmonary edema
and the accumulation of inflammatory cells in the lung,
with histopathologic features of acute lung injury (ALI)
and acute respiratory distress syndrome (ARDS), the most
severe form of ALI. These lung injuries directly correlate
with influenza-associated morbidity and mortality because
of the impairment of gas exchange and respiratory func-
tions. ARDS is characterized by an increase in the perme-
ability of the alveolar-capillary barrier, which is formed by
the microvascular endothelium and the alveolar epithe-
lium, leading to an influx of fluid and leukocytes into the
alveolar airspace across both the endothelium and thean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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causes of death following infections with pandemic 2009
H1N1 and highly pathogenic avian H5N1 influenza viruses
(Perrone et al. 2008; Zhang et al. 2012b).
Several experimental studies have shown that influenza-
induced death is suppressed by anti-inflammatory agents
that counteract the inflammatory response of the hosts
without affecting virus replication itself (Darwish et al.
2011; Garcia et al. 2010). These reports indicate that sup-
pression of the heightened inflammatory response to viral
infection is important in order to avoid influenza-caused
death.
Oral or intranasal administrations of lactic acid bacteria
are effective against influenza A virus infection (Izumo
et al. 2010; Maeda et al. 2009). These bacterial adminis-
trations help to enhance host’s immune response that
causes the reduction of the viral replication efficiency
and/or upregulation of cytokine expression. Previously,
we reported that the water-soluble fraction of lysozyme-
treated lactic acid bacterium Enterococcus faecalis FK-23
(LFK) reduces the mortality associated with influenza A
virus infections (Kondoh et al. 2012). However, the mech-
anism underlying the anti-influenza effect of LFK remains
unclear. We previously reported that the oral administra-
tion of LFK attenuates the eosinophil influx into the upper
airway in a murine allergic model (Zhu et al. 2012) and the
inflammatory cell influx into bronchoalveolar lavage fluid
(BALF) in a murine asthmatic model (Zhang et al. 2012a).
These results implied the possibility of anti-inflammatory
effect of LFK during influenza virus infection. In this study,
we demonstrate that the administration of LFK reduces
mortality after H1N1 viral infection and suppresses the
excessive influx of leukocytes, which cause inflamma-
tory reactions, into lungs via modulation of the alveolar-
capillary permeability.
Results
Reduction of the mortality of influenza virus-infected
mice by LFK administration
To test for preventive effect against influenza, we orally
administered LFK to mice at a dose of 15 mg per mouse,
once daily, for 6 days before and 17 days after the viral
infection, and monitored the survival rate for 17 days
after the infection (Figure 1A). In this experiment, the
LFK dose was fixed at 15 mg per mouse as previous re-
port in which water-soluble fraction of LFK suspension
(15 mg per mouse) was administered to mice (Kondoh
et al. 2012). However, in this experiment, LFK suspension
rather than water-soluble fraction of LFK was administered
for comprehensive understanding of the mechanism for
prevention of influenza by LFK. As shown in Figure 1B,
16% of mice in the control group, which were administered
saline orally, survived for 17 days post-infection. In con-
trast, 45% of mice administered LFK orally survived afterinfection. This result indicates that oral administration of
LFK provides effective protection from lethal infection by
influenza A virus.
Next, we examined whether the improved survival was
due to a reduction in the viral replication efficiency in the
lung, because oral or intranasal administration of lactic
acid bacteria was shown to suppress viral replication effi-
ciency in the lung (Maeda et al. 2009; Izumo et al. 2010).
In contrast to these reports, the viral titer in lungs showed
no significant difference between the saline- and LFK-
administered groups at 3 days, 5 days, and 7 days post-
infection (DPI) (Figure 1C). This result suggests that the
mechanism by which oral administration of LFK protects
against virus-induced death is different from that reported
for other lactic acid bacteria.
Suppression of the infiltration of leukocytes into lung
after virus-infection by LFK treatment
Leukocytes, including inflammatory cells, mononuclear
cells, and lymphocytes, infiltrate into the lung area after
viral infection (Kohlmeier and Woodland 2009; Fukushi
et al. 2011). To gain insight into the protective mechan-
ism underlying LFK activity, we stained the lung sections
using hematoxylin-eosin (HE). This staining revealed
that infiltration of leukocytes into the pulmonary paren-
chyma was suppressed at DPI-7 in the LFK-administered
group, whereas infiltration of leukocytes in the pulmon-
ary parenchyma and alveolar collapse were observed in
the saline-administered group (Figure 2A and Additional
file 1: Figure S1). To confirm that LFK suppresses the infil-
tration of leukocytes, we homogenized the removed lungs
and counted the number of whole lung cells by using a
microscope. In the saline-administered group, the number
of lung cells increased after viral infection and reached a
maximum at DPI-7 (Figure 2B). Unlike in the control
group, the number of these cells in the LFK-administered
group was significantly suppressed at DPI-5, DPI-7, and
DPI-10 (Figure 2B). Similar results were obtained for BALF
cells. The total cell number in the BALF was suppressed in
the LFK-administered group at DPI-5 compared to that in
the saline-administered group (Figure 2D).
Upregulation of type II pneumocyte number by LFK
administration
Surprisingly, the number of whole lung cells at DPI-0
was significantly higher in mice that were administered
with LFK for 6 days before viral infection than in the
saline-administered group (Figure 2B). The alveolar septa
consists of 2 types of pneumocytes (type I and II), connect-
ive tissues, and blood vessels (Rogers 2010). We performed
an immunohistochemical analysis because, on the basis of
our observation of the HE-stained lung sections at DPI-0
(Additional file 2: Figure S2A), we expected an increase in
the number of type II pneumocytes. Staining with type II
Figure 1 (See legend on next page.)
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Figure 1 Administration of LFK protects mice from influenza virus PR8-induced death. (A) The experimental protocol for oral administration and
infection with influenza A/PR/8. The vertical arrows indicate oral administration of LFK (15 mg/head, dissolved in 200 μl saline) or saline from day −6 to
day 17. The triangle on day 0 indicates the inoculation with PR8 (1,000 PFU/mouse). (B) Survival rate of mice after the infection with PR8 (saline-
administered group: circle, n= 19; LFK-administered group: triangle, n= 20). Statistically significant difference between saline and control mice is indicated
by P value (P < 0.05 by the log-rank test). (C) Viral titers in the lungs after inoculation with PR8. Mean viral titers ± standard deviations are shown. Each
group consists of 6 to 7 mice.
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showed that the number of type II pneumocyte was
upregulated in the LFK-administered group compared to
that in the saline-administered group (Additional file 2:
Figures S2B and S2C).
Suppression of cellular infiltration independent of cell type
Next, we evaluated which types of cells infiltrate into the
lung area after viral infection. Cell populations of each
leukocyte in the lung were analyzed at DPI-0, DPI-3,
DPI-5, DPI-7, and DPI-10 using a flow cytometer. In the
early phase of infection with influenza virus, innateFigure 2 Administration of LFK suppresses the leukocytes infiltration
section stained with HE at DPI-7 (left: non-infected control, middle: saline-a
Original magnification is X10. Scale bars indicate 100 μm. (B) The lung cells
absolute number of lung cells was counted (*: P < 0.01, **: P < 0.05, Studen
groups, respectively (DPI-0: saline n = 7, LFK n = 7; DPI-3: saline n = 5, LFK n
saline n = 3, LFK n = 5). (C) The change in lung cell population (blue: saline-
through a flow cytometer (DPI-0: saline n = 7, LFK n = 7; DPI-3: saline n = 5,
DPI-10: saline n= 3, LFK n= 5). (D) The total number of BALF cells at DPI-5 was
group, n= 6; *, P < 0.05, Student’s t test). (E) Cell population in BALF was ana
red: LFK-administered group, n= 6).immune cells, such as monocytes, macrophages, and neu-
trophils, were recruited to the lung at DPI-5 and DPI-7
(Figure 2C). Thereafter, T cell migration was observed
(Figure 2C). However, there was no significant difference
between the saline- and LFK-administered groups in the
population of the infiltrating cells. A similar result was
obtained for the cell population in the BALF at DPI-5. The
saline- and LFK-administered groups showed no significant
difference in the population of leukocytes that infiltrated
the alveolar space (Figure 2E). These results indicate that
the suppression of cellular infiltration into the lung oc-
curred in all types of leukocytes that we analyzed.into the lungs after PR8 viral infection. (A) Histology of lung tissue
dministered mice at DPI-7, right: LFK-administered mice at DPI-7).
were isolated at DPI-0, DPI-3, DPI-5, DPI-7 and DPI-10, and the
t’s t test). Blue and red squares indicate saline- and LFK-administered
= 4; DPI-5: saline n = 5, LFK n = 4; DPI-7: saline n = 5, LFK n = 5; DPI-10:
administered group, red: LFK-administered group) was analyzed
LFK n = 4; DPI-5: saline n = 5, LFK n = 4; DPI-7: saline n = 5, LFK n = 5;
counted (blue: saline-administered group, n= 8; red: LFK-administered
lyzed through a flow cytometer (blue: saline-administered group, n= 8;
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infection
Chemokines regulate the trafficking of various types of leu-
kocytes, and cytokines can induce the production of
chemokines (Kohlmeier and Woodland 2009). Therefore,
we next evaluated the mRNA expression level of cytokines
and chemokines in the lung during the course of viral
infection. The expression level of various Th1 cytokines,
pro-inflammatory cytokines, CCL-chemokine ligands, and
CXCL-chemokine ligands were elevated after the viral in-
fection (Figure 3A, 3B, and Additional file 3: Figure S3A
and S3B). However, no significant difference in the expres-
sion level of cytokines and chemokines was observed ex-
cept for CXCL4 (platelet factor 4), which on its own does
not show any chemotactic activity to leukocytes (Kasper
and Petersen 2011).
Suppression of virus-induced alveolar-capillary
permeability by LFK treatment
Next, we examined whether the suppression of leukocyte
migration was due to the changes in pulmonary alveolar-
capillary permeability, because pulmonary inflammation
during viral infection is closely correlated with the break-
down of pulmonary barrier integrity (Steinberg et al. 2011;
Fukushi et al. 2011). The change in alveolar-capillary per-
meability was assessed by monitoring the extravasation of
Evans blue dye into the BALF. As shown in Figure 4A, in-
creases in virus-induced Evans blue accumulation were
suppressed at DPI-7 in the LFK-administered mice. This
indicates that the administration of LFK suppresses viral
infection-induced pulmonary permeability, and that the
suppression of inflammatory cell influx by LFK is due to
stabilization of the alveolar-capillary barrier integrity.
Modulation of gene expression controlling the vascular
permeability by LFK administration
Mechanisms that control vascular permeability during
inflammation have been reported. Matrix metallopro-
teinases (MMPs) are important regulatory enzymes in
pro-inflammatory pathways, and their expression and
activities are typically increased during the inflammatory
process. MMPs degrade major components of the vascu-
lar basement membrane and extracellular matrix, such
as gelatin and collagen, in the alveolar-capillary barrier
(Manicone and McGuire 2008). Therefore, we investi-
gated the mRNA expression level of MMPs in the lung
during the course of viral infection. MMP-7 expression
following viral infection was suppressed in the LFK-
administered group at DPI-7 (Figure 4B). For the other
MMPs, a decreasing trend was observed in the LFK-
treated group at DPI-7 (Figure 4B). These results suggest
that the downregulation of MMP expression by LFK-
administration could attenuate the vascular permeability
caused by viral infection.Discussions
A number of probiotic bacteria, including Bifidobacteria
and lactic acid bacteria such as Lactobacillus, have an
anti-influenza effect that is achieved by the reduction of
viral replication efficiency and/or upregulation of Th1
cytokine expression through the activation of the host’s
immune system (Harata et al. 2010; Yasui et al. 2004;
Maeda et al. 2009; Izumo et al. 2010). We previously
reported that oral administration of the soluble com-
ponents of LFK, lysozyme-treated lactic acid bacteria
E. faecalis FK-23, has an anti-influenza effect by up-
regulation of the anti-inflammatory cytokine IL-10 in lung
(Kondoh et al. 2012). However, administration of the LFK
suspension did not markedly upregulate IL-10 expression
in this study (Figure 3A). This discrepancy could be due to
the differences in composition between administered sam-
ples. In this report, LFK suspension was administered to
mice, while the supernatant of LFK suspension after centri-
fuge was used in the previous report (Kondoh et al. 2012).
The present study demonstrated that LFK suspension
has the ability to neither repress the viral replication,
nor enhance the immune system in the lungs (Figures 1C,
3, and Additional file 3: Figure S3). These results indicate
that the mechanism by which oral administration of LFK
protects against virus-induced death is different from that
reported for other probiotic bacteria.
Pneumocytes play pivotal roles in pulmonary function:
(1) lung surfactants secreted by pneumocytes prevent al-
veolar collapse (Griese 1999), (2) type II pneumocytes
are progenitor cells for alveolar epithelium during injuries
(Mason 2006), and (3) type I pneumocytes are responsible
for oxygen and carbon dioxide exchange (Mason 2006). In
Figure S2, we demonstrated that oral administration of
LFK increases the number of type II pneumocytes, which
act as alveolar epithelial stem cells (Fehrenbach 2001).
However, further experiments, such as immunohistochem-
ical analysis using antibodies against proliferation marker
and mitogen, are required to clear how the proliferation is
induced by LFK. Influenza virus infection against type II
pneumocyte causes damage to the alveolar epithelial cells
and/or the cell death (Matute-Bello et al. 2001; van Riel
et al. 2007; Loosli et al. 1975). The damage and/or loss re-
sult in disturbances in fluidity at the alveolar-capillary
border, which is associated with gas exchange inefficiency
and pulmonary vascular permeability (Mura et al. 2010;
Ware and Matthay 2000; Matute-Bello et al. 2001). There-
fore, the increase in the number of type II pneumocytes in
the LFK-administered group suggests that LFK might have
the effect of improving respiratory function and epithelial
barrier function by the proliferation and/or differentiation
of type II pneumocyte during viral infection. Another pos-
sibility is that the increase in the number of type II
pneumocytes might cause the lower multiplicity of the
virus in the virus-infected pneumocyte, which leads to the
Figure 3 Cytokine and chemokine mRNA expression levels during the course of the viral infection. (A) Cytokine mRNA expression level in
lung. (B) Chemokine mRNA expression level in lung. Each value is expressed as fold change compared to non-infected control mice (*: P < 0.01,
Student’s t test). Gray, white, and black columns indicate non-infected control (n = 3), saline-administered (n = 6), and LFK-administered (n = 6)
groups, respectively.
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sive vascular permeability. However, further analysis of the
induction of cell death, proliferation, and differentiation in
the type II pneumocyte is required to unmask the role of
the increased pneumocyte in LFK-administered mice dur-
ing the influenza virus infection.
Cytokines and successive chemokines are produced
following influenza virus infection in the lungs as earlyanti-viral responses (Kohlmeier and Woodland 2009). In
the present study, the expression of cytokines and
chemokines after viral infection were not modulated by
the treatment with LFK, except for CXCL4 (Figure 3), al-
though the reported probiotic bacteria regulate the ex-
pressions as a viral defense mechanism (Maeda et al.
2009; Yasui et al. 2004). This is supported by our unpub-
lished data that show that elimination of peptidoglycan
Figure 4 Administration of LFK suppresses the virus-induced alveolar-capillary permeability in lungs. (A) Alveolar-capillary permeability
was assessed by extravasation of Evans blue dye into BALF at DPI-5 and DPI-7. Permeability index was determined from the dye content of BALF
compared with serum (DPI-5: saline n = 5, LFK n = 6; DPI-7: saline n = 5, LFK n = 5; *: P < 0.05, Student’s t test). (B) MMP mRNA expression level in
lung. Each value is expressed as fold change compared to non-infected control mice (*: P < 0.05, Student’s t test). Gray, white, and black columns
indicate non-infected control (n = 4), saline-administered (n = 4), and LFK-administered (n = 4) groups, respectively.
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ation results in loss of the ability to produce various cy-
tokines in ex vivo culture of the splenocytes from mice
(data not shown). Increased influx of leukocytes into alveo-
lar space occurs after viral infection, and leukocyte extrava-
sation from the blood to the inflamed tissue is a controlled
process involving rolling, adhesion, and migration (Weber
et al. 2007). While CXCL4 shows no chemotactic activity
against leukocytes, CXCL4 enhances monocyte adhesion
to the endothelium and neutrophil extravasation to the
inflamed lung via heterophilic interaction with CCL5
(Grommes et al. 2012; von Hundelshausen et al. 2005;
Kasper and Petersen 2011). Therefore, our results suggest
that the suppression of leukocyte migration into the lung
by the administration of LFK is partially mediated by the
downregulation of CXCL4 expression.
MMPs induced by influenza virus infection degrade
the components of the vascular basement membrane
and extracellular matrices, and the resulting dysfunctionof the alveolar-capillary barrier contributes to pathogenesis
(Ng et al. 2012; Wang et al. 2010; Davey et al. 2011;
Manicone and McGuire 2008). MMP-7 is reported to de-
grade not only VE-cadherin but also E-cadherin, which are
major components of endothelial and epithelial adherens
junctions, respectively (McGuire et al. 2003; Ichikawa et al.
2006). These adherens junctions act as gatekeepers for the
passage of leukocytes during inflammation. Furthermore,
stabilization of vascular barrier integrity by upregulating
the expression of the VE-cadherin mRNA reduces mortal-
ity after H5N1 viral infection and suppresses leukocyte in-
flux into the lung (London et al. 2010). Therefore, our
results suggest that downregulation of the expressions of
MMP-7 and other MMPs by LFK attenuates not only the
breakdown of adherens junctions of alveolar epithelial and
vascular endothelial cells, but also degradation of the
vascular basement membrane and extracellular matrices.
However, further analyses for protein level of MMP and
MMP-mediated degradation of target proteins would be
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LFK for the prevention of influenza.
The components of LFK to exert the anti-influenza ef-
fect remain unidentified. Since a recent study has dem-
onstrated that the soluble peptidoglycan of commensal
bacteria translocates from the intestine to the systemic
circulation (Clarke et al. 2010), one possibility is that the
lysozyme-degraded components of peptidoglycan could
translocate to the lungs, thereby modulating the alveolar-
capillary barrier. Identification of the active components in
LFK will be essential to further understand the precise
anti-influenza mechanism.
In this study, we demonstrated that the administration
of LFK improved survival rates and suppressed the infil-
tration of leukocytes into the lung after viral infection.
Several factors could contribute to the effect of LFK
against influenza virus infection. These include the sup-
pression of leukocyte infiltration into the lungs by both
the downregulation of CXCL4 expression and the modu-
lation of pulmonary endothelial-epithelial permeability
via the increase of type II pneumocytes and the repression
of MMPs expression. Our findings support the notion that
suppression of the breakdown of the alveolar-capillary bar-
rier and the subsequent leukocyte influx into the lung
would improve the survival rate after viral infection.
Stabilization of pulmonary alveolar-capillary barrier integ-
rity using bacterial components might be a useful strategy
for managing seasonal and pandemic influenza.
Methods
LFK preparation
E. faecalis strain FK-23 was cultured in broth medium
containing 2.5% of glucose, 1.4% of yeast extract, 0.8% of
peptone, and 4.4% of K2HPO4 for 18h at 37°C, and the
cultures were harvested by centrifugation. After washing
with distilled water, the bacteria were treated with lyso-
zyme, and then the reaction mixture was heated to 110°C
for 10 min before lyophilization as described previously
(Kondoh et al. 2012). LFK (15 mg/head, dissolved in 200 μl
saline) or saline (200 μl) was orally administered using a
feeding needle once a day.
Virus preparation
An influenza virus strain, A/Puerto Rico/8/34 (H1N1;
PR8) was used in this study. The infectious materials were
handled in a biosafety level 2 facility under approved proto-
cols in accordance with guidelines of Hokkaido University.
The virus was prepared as described previously (Kondoh
et al. 2012). In brief, the virus was propagated in the al-
lantoic cavities of 10-day-old embryonated chicken eggs
at 35°C for 48 h, and then was concentrated and purified
by density gradient centrifugation. The purified virus was
suspended in phosphate-buffered saline (PBS) and stored
at −80°C until use.Mice and viral infection
Male C57BL/6N mice (6 weeks old) were purchased
from CLEA Japan. Mice were housed in isolator cages in
a biosafety level 2 room (12 h light/dark cycle) with free
access to standard diet (CE-2; CLEA Japan) and tap
water. We performed animal care and experiments in
accordance with guidelines and approval of the Animal
Care and Use Committee of Hokkaido University (08–
0231). All surgery was performed under isoflurane an-
aesthesia. Mice were lightly anesthetized with isoflurane
(Dainippon Pharmaceutical, Osaka, Japan) and inocu-
lated intranasally with 103 PFU at 50 μl in both nostrils
on day 0. The survival rate and body weight were moni-
tored daily until 17 days after the viral infection. To
minimize suffering after viral challenge, mice were carefully
observed each day and mice reaching approved endpoint
criteria were euthanized by overdose of isoflurane. Mice
were euthanized by overdose of isoflurane on day 17 after
the infection.
Viral titration
Plaque forming assay was performed as described previ-
ously (Fukushi et al. 2011) with some modifications of the
protocol. Mice were sacrificed by isoflurane inhalation and
lung was removed from the mice. The lungs were com-
pletely homogenized in 1X MEM medium using Micro
smash (Tomy Seiko, Tokyo, Japan), and the homogenates
were serially diluted with cold PBS. For a plaque assay,
Madin-darby canine kidney (MDCK) cells were plated in a
flat bottomed 12 well plate 24 h before infection. Superna-
tants from lung homogenates serially diluted were used to
infect the confluent MDCK cells at 37°C for 1h. The cells
were washed and subsequently overlaid with MEM mixed
with 0.8% Bacto-agar (Difco, Sparks, USA) in the presence
of trypsin (5 μg/ml). The plates were incubated at 35°C for
2 days and the plaques were counted.
Histological analysis
Mice were sacrificed by isoflurane inhalation and lung
was removed from the mice. Removed lungs were im-
mediately fixed in 10% PBS-buffered formalin. Paraffin-
embedded tissues were sectioned to a thickness of 4 μm
and stained with hematoxyline and eosin (Merck, USA)
using standard histological techniques. For immune-
histochemical study, the paraffin-embedded tissue sections
were incubated with anti-prosurfactant protein C antibody
which is a type II pneumocyte marker (Millipore, Billerica,
USA), incubated with horseradish peroxidase labeled
polymer anti rabbit system (DAKO, Glostrup, Denmark),
developed with envision + system HRP labeled polymer
anti-rabbit (DAKO Glostrup, Denmark), and counter-
stained with hematoxylin (Merck, USA) in accordance
to manufacturer’s instructions. The proportion of pro-
surfactant protein C positive cells was calculated by
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positive cells in 6 random microscopic fields at a magni-
fication of 40.
Flow cytometric analysis of lung and BALF cells
Mice were sacrificed by isoflurane inhalation and lung
was removed from the mice. Lung tissue was homoge-
nized using gentleMACS dissociator (Miltenyi Biotech,
Bergisch Gladbach, Germany) in C tube (Miltenyi Biotech,
Bergisch Gladbach, Germany) containing HEPES buffer
(pH 7.4) with 2 μg/ml of collagenase-D (Roche, Basel,
Switzerland) and 40 U/ml of DNase I (Takara bio, Otsu,
Japan), and then incubated for 30 min at 37°C with gentle
rotation. After centrifugation, cells were treated with lysis
buffer (BD Biosciences, Franklin lakes, USA) according to
manufacture’s instruction. The bronchoalveolar lavage fluid
(BALF) cells were collected using a 24G catheter (Terumo,
Tokyo, Japan) by insertion of PBS from the trachea. Num-
ber of lung and BALF cells was counted using a Neubauer
hemocytometer (Erma, Tokyo, Japan). Cells were incubated
with monoclonal antibody 2.4G2, and stained with FITC-
conjugated anti-CD3e (BD Biosciences, clone 145-2C11)
for T-cell (CD3e+) analysis, with FITC-CD11b (BD Biosci-
ences, clone MI/70) and PE-Ly6G (BD Biosciences, clone
1A8) for neutrophils (CD11bhigh Ly6Ghigh) and monocytes
(CD11bhigh Ly6Gmed) analyses, with FITC-CD49b (BD Bio-
sciences, clone DX5) for NK cells (CD49b+) analysis, with
FITC-B220 (Biolegend, clone RA3-6B2) for B cells (B220+)
analysis, or with APC-CD11c (Biolegend, clone N418) and
PE/Cy7-F4/80 (Biolegend, clone BM8) for dendritic cell
(CD11c+ F4/80-) and macrophages (F4/80+) analyses. The
stained cells were analyzed with FACSCanto II flow
cytometer (BD Biosciences).
Real time PCR
Real time PCR reaction was performed as described
previously (Kondoh et al. 2012). In brief, total RNA
was extracted from whole lung homogenates using
TRIzol reagent (Invitrogen, Carlsbad, USA) and Micro
smash (Tomy Seiko, Tokyo, Japan), and then treated
with DNase I (Takara bio, Otsu, Japan). The cDNA
was synthesized using oligo dT20 primers (Toyobo,
Osaka, Japan), random primers (Toyobo, Osaka, Japan)
and ReverTra Ace (Toyobo, Osaka, Japan). Each pro-
cedure was performed according to the manufacture’s
instructions. Real time PCR was performed using SYBR
Premix Ex Taq II (Takara bio, Otsu, Japan) with the
MX3000P real time PCR system (Stratagene, La Jolla,
USA). Cycling conditions were used as: 95°C for 10 sec
to activate DNA polymerase, followed by 40 cycles of
95°C for 5 sec and 60°C for 30 sec. Expression levels of
each mRNA were represented as relative expression
amounts, which were normalized with glyceraldehyde-
3-phosphate dehydrogenase (GAPDH).Measurement of alveolar-capillary permeability
Alveolar-capillary leakage after viral infection was deter-
mined using Evans blue dye as described previously
(Rhein et al. 2008). Two hours before killing, mice were
injected intravenously via retro orbital sinus under
isoflurane anaesthesia with 0.2 ml of 5 mg/ml Evans blue
in PBS. BALF and serum were collected after killing
mice with isoflurane and the optical density was deter-
mined at 600 nm. The permeability changes were evalu-
ated by the BALF/serum concentration ratio.
Statistical analysis
The data are expressed as means ± standard deviations
(SD). A student’s t test was used for statistical analysis.
The Kaplan-Meier method with the log-rank test was
used for analysis of mortality. P value of <0.05 was con-
sidered to be significant.
Additional files
Additional file 1: Figure S1. Histology of lung tissue section stained
with HE at DPI-7. Original magnification is X20 (A: non-infected control,
B: saline-administered mice at DPI-7, C: LFK-administered mice at DPI-7). Scale
bars indicate 100 μm. In each group, two fields, which were taken from lung
section of different mice, are shown.
Additional file 2: Figure S2. Increased number of Type II
pneumocyte by the administration of LFK. (A) Histology of lung tissue
section stained with HE at DPI-0 (top: saline-administered mice, bottom:
LFK-administered mice). Original magnification is X4. Scale bars indicate
250 μm. (B) Immunohistochemical staining of lung tissue section at DPI-0
using prosurfactant protein C (proSP-C) antibody (top: saline-administered
mice, bottom: LFK-administered mice). Arrowheads indicate examples of
proSP-C-positive cells. Original magnification is X40. Scale bars indicate
50 μm. (C) The proportion of proSP-C positive cells was counted in 6
random microscopic fields for each group at a magnification of X40
(blue: saline, red: LFK; *: P < 0.01, Student’s t test).
Additional file 3: Figure S3. Cytokine and chemokine mRNA expression
levels during the course of the viral infection. (A) Cytokine mRNA expression
level in lung. (B) Chemokine mRNA expression level in lung. Each value is
expressed as fold change compared to non-infected control mice (*: P < 0.01,
Student’s t test). Black, blue, and red columns indicate non-infected control
(n = 3), saline-administered (n= 6), and LFK-administered (n= 6) groups,
respectively.
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